References

• About COVID-19. (n.d.). Retrieved October 28, 2020, from http://www.bccdc.ca/health-info/disea...
• Cao, Y., Deng, Q., & Dai, S. (2020). Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease, 35, 101647. https://doi.org/10.1016/j.tmaid.2020....
• Cohen F. S. (2016). How Viruses Invade Cells. Biophysical journal, 110(5), 1028–1032. https://doi.org/10.1016/j.bpj.2016.02...
• Coronavirus disease (COVID-19). (2020, October 10). Retrieved October 28, 2020, from https://www.canada.ca/en/public-healt...
• FDA. (2020, October 22). FDA approves first treatment for COVID-19. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press...
• Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020). Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. The Journal of biological chemistry, 295(20), 6785–6797. https://doi.org/10.1074/jbc.RA120.013679
• Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., … Flanigan, T. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 382(24), 2327–2336. https://doi.org/10.1056/nejmoa2007016
• Hendaus, M. A. (2020). Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2020...
• Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., …
• Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20...
• Razonable R. R. (2011). Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 86(10), 1009–1026. https://doi.org/10.4065/mcp.2011.0309
• Saha, A., Sharma, A. R., Bhattacharyac, M., Sharma, G., Lee, S., & Chakrabortya, C. (2020). Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more. Archives of Medical Research, 51(6), 585-586. https://doi.org/10.1016/j.arcmed.2020...
• Vardanyan, R., & Hruby, V. (2006). Antiviral Drugs. Synthesis of Essential Drugs, 549–557. https://doi.org/10.1016/b978-04445216...
• Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181(2), 281–292.e6. https://doi.org/10.1016/j.cell.2020.0...
• Wilt, T. J., Kaka, A. S., Macdonald, R., Greer, N., Obley, A., & Duan-Porter, W. (2020). Remdesivir for Adults With COVID-19. Annals of Internal Medicine. https://doi.org/10.7326/m20-5752
• Yin, W., Mao, C., Luan, X., Shen, D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., Chang, S., Xie, Y., Tian, G., Jiang, H., Tao, S., Shen, J., Jiang, Y., Jiang, H., Xu, Y., … Xu, H. E. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 368(6498), 1499-1504. https://doi.org/10.1126/science.abc1560